An Epidemiologic Review of Marijuana and Cancer: An Update
Yu-Hui Jenny Huang¹, Zuo-Feng Zhang², Donald P. Tashkin³, Bingjian Feng⁴, Kurt Straif⁵, and Mia Hashibe¹

Abstract
Marijuana use is legal in two states and additional states are considering legalization. Approximately 18 million Americans are current marijuana users. There is currently no consensus on whether marijuana use is associated with cancer risk. Our objective is to review the epidemiologic studies on this possible association. We identified 34 epidemiologic studies on upper aerodigestive tract cancers (n = 11), lung cancer (n = 6), testicular cancer (n = 3), childhood cancers (n = 6), all cancers (n = 1), anal cancer (n = 1), penile cancer (n = 1), non-Hodgkin lymphoma (n = 2), malignant primary gliomas (n = 1), bladder cancer (n = 1), and Kaposi sarcoma (n = 1). Studies on head and neck cancer reported increased and decreased risks, possibly because there is no association, or because risks differ by human papillomavirus status or geographic differences. The lung cancer studies largely appear not to support an association with marijuana use, possibly because of the smaller amounts of marijuana regularly smoked compared with tobacco. Three testicular cancer case-control studies reported increased risks with marijuana use [summary ORs, 1.56; 95% confidence interval (CI), 1.09–2.23 for higher frequency and 1.50 (95% CI, 1.08–2.09) for ≥10 years]. For other cancer sites, there is still insufficient data to make any conclusions. Considering that marijuana use may change due to legalization, well-designed studies on marijuana use and cancer are warranted.

Cancer Epidemiol Biomarkers Prev; 24(1); 15–31. ©2015 AACR.

Introduction
In July 2014, the New York Times Newspaper Editorial Board called for marijuana to be legalized in the United States (1). Regarding potential health issues that marijuana may cause, a New York Times article cited a New England Journal of Medicine review and mentioned that the link with lung cancer was unclear and if there is any increased risk, it is lower than that of cigarette smoking (2). The New England Journal of Medicine article that was cited reported that the association between marijuana use and cancer could not be ruled out (3). Certainly, the potential benefits of medical marijuana use must be considered and weighed against the harms, but the potential role of marijuana smoking in causing cancer needs to be carefully reviewed.

In 2012, Colorado and Washington legalized marijuana use for adults age 21 years or older (4). Medical marijuana is legal in 23 states and the District of Columbia with laws that have been changing over the time period between 1996 and 2014 (5). The states which permit medical marijuana include Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, and Washington (5). Nevertheless in more than half of the states, it is still illegal for people to use, buy, sell, possess, cultivate, and transport marijuana. Also, it is illegal to sell marijuana to those under 21 by law. However, 14 additional states are currently considering legalization of marijuana (6).

In 2012, 18.7% of young adults (ages 18–25 years), 7.2% of children (12–17 years of age), and 5.3% of adults ≥ age 26 years used marijuana in the past month, and 40.3% of past-month marijuana users (5.4 million) used it daily or nearly daily. Moreover, since 2002, and especially after 2007, near-daily use of marijuana in persons 12 years of age and older has increased steadily (7) at the same time that perceived risk from marijuana has declined (8). Among American adults, approximately 18 million people (7.6%) were current marijuana users (9) in contrast to an estimated 42.1 million (18.1%) current cigarette smokers (10). In 2012, there were approximately 6,600 new marijuana users each day (7). The increasing trends in marijuana use prevalence over the past several years, along with the declining perceptions of health risks from marijuana and greater availability of marijuana in states where it has been legalized for medical or recreational use, suggest that it is likely (albeit not certain) that the prevalence of marijuana use will continue to increase.

In 2005, we published an epidemiologic review of marijuana use and cancer risk, including articles published up to November 2004 (11). The 2005 review included two cohort studies and 14 case-control studies, with an assessment that there were not sufficient studies available to adequately evaluate the impact of marijuana on cancer risk. The limitations in previous studies included possible underreporting where marijuana use is illegal, small sample sizes, and too few heavy marijuana users in the study. In this current review, our objective is to provide an updated review including these previously reviewed studies as
well as additional articles published. We will evaluate whether there is evidence to support an association between marijuana use and cancer risk, or support the lack of association.

Materials and Methods

We used the keywords "marijuana," "cannabis," and "cancer" on PubMed/Medline and identified epidemiologic studies on marijuana use and cancer risk, published up to August 2014. We also reviewed the literature citation of each of the publications identified. Epidemiologic studies for which investigators assessed marijuana use and provided risk estimates for marijuana exposure were included in our review. Study design, subject recruitment methods, and risk estimates reported for these studies are presented in the tables, ordered by publication date. For each study, we chose the best estimates from the publication to present in the tables, such as RR or OR among never smokers and RR or OR adjusted for potential confounders, including tobacco smoking. We also show the cancer risk estimates by frequency and/or duration if those estimates were available, prioritizing cumulative exposure estimates (joint-years), if available.

We conducted a meta-analysis when at least three combinable ORs were available and the exposure variable was comparable. The three studies on marijuana use and testicular cancer met this criterion as the exposure categories were fairly comparable for combining estimates. For head and neck cancer, a meta-analysis was not warranted considering that subgroups by human papilloma virus (HPV) status and geographic region appeared to be important for the marijuana and cancer association (i.e., combining estimates is not appropriate). For lung cancer, a meta-analysis was not warranted because most studies did not report any association and a large consortium pooled analysis had recently been published. For childhood cancers, the cancers covered by the studies were very heterogeneous, thus a meta-analysis was not warranted. Summary ORs were estimated with the statistical program STATA, version 12.1, by inverse-variance weighting, using a random-effects model that included a term for heterogeneity among the studies. Tests for heterogeneity among the studies were conducted for each analysis.

Results

Four cohort studies and 30 case-control studies were identified for investigations of marijuana use and cancer risk. They included 11 studies on upper aerodigestive cancers (12–22), six studies on lung cancer (16, 23–27), three studies on testicular germ cell tumors (28–30), six studies on childhood cancers (31–36), one study on all cancers (37), one study on anal cancer (38), one study on penile cancer (39), two studies on non-Hodgkin lymphoma (40, 41), one study on malignant primary gliomas (42), one study on bladder cancer (43), and one study on Kaposi sarcoma (44).

Upper aerodigestive tract cancer

A hospital-based case-control study of 173 cases and 176 controls in New York reported a 2.6-fold increase [95% confidence interval (CI), 1.1–6.6] in head and neck cancer risk due to marijuana use (ref. 12; Table 1). Dose-response trends were observed for both frequency (times per day) and duration (years) of marijuana use in this study. In contrast, a population-based study in Washington of 407 cases and 615 controls reported no association between marijuana use and oral cavity cancer risk (13). Two small studies in the United Kingdom (116 and 53 cases) reported no association between oral and oropharyngeal cancer risk and cannabis smoking, and did not report on any dose-response trends (14, 15).

In the Los Angeles population-based case-control study, no increased risk of head and neck cancers [oral cavity (n = 303), pharynx (n = 100), larynx (n = 90)] or esophageal cancer (n = 108) was observed among ever users of marijuana after adjusting for age, gender, race/ethnicity, educational level, alcohol consumption, and tobacco cigarette smoking (16). No association between marijuana use among never-tobacco cigarette smokers and head and neck cancer was observed; however, the risk estimates were not very precise. The limitations of the study were potential recall bias, downward bias in OR estimation due to nonparticipation greater in exposed cases than in unexposed controls, and potential underreporting of past marijuana use. The strengths of the study included the population-based study design, collecting the data with assurance to the study subjects that all information provided would be kept confidential, and estimating risk among never-tobacco smokers to minimize the potential effect of residual confounding by tobacco smoking.

In a case-control study in New Zealand, Aldington and colleagues (17) reported no association between ever use of cannabis and head and neck cancer risk, and no dose-response relation for joint-years of cannabis use after adjusting for age, sex, ethnicity, alcohol consumption, income, and pack-years of cigarette smoking. The study included 75 cases age <55 years old and 319 controls matched by age and district health boards in New Zealand from 2001 to 2005. The limitations of this study included the small sample size and inclusion of many head and neck cancer sites with various etiologies (e.g., nasopharyngeal cancer, nasal cavity cancer). Strengths of this study included the population-based design and the focus on a cohort of subjects who were likely to have higher marijuana prevalence (<5 years old in the study).

Gillison and colleagues (18) reported on a strong association between marijuana use and HPV-16-positive head and neck cancer risk after adjusting for race, tobacco smoking, alcohol drinking, number of teeth lost, frequency of tooth brushing, and number of oral sex partners in a hospital-based case-control study. Dose-response relations for number of joints usually smoked per month and for years of marijuana smoking were observed. This study included 240 cases and 322 controls matched by age and sex to each HPV-16-positive and HPV-16-negative case subject recruited at the Johns Hopkins Hospital from 2000 to 2006. Limitations of this study were potential recall bias, possible misclassification of tumor HPV status, potential confounding by use of other substances, and that the general population may not have been represented by the control population. This is one of the few studies, on the other hand, that has explored marijuana use for head and neck cancer, stratified on HPV infection status, which is a strong risk factor for oropharyngeal cancers.

In the International Head and Neck Cancer Epidemiology (INHANCE) consortium pooled data analysis, including three hospital-based case-control studies and two population-based case-control studies, Berthiller and colleagues (19) did not observe any associations between smoking marijuana and the risk of head and neck cancer after adjusting for age, sex, race, study, education level, and alcohol duration. This pooled analysis included the Los Angeles study (493 cases and 1,040 controls; ref. 16) and the Seattle study (407 cases and 615 controls; ref. 13). The other studies included in the pooled analysis did not publish
Table 1. Epidemiologic studies on marijuana use and upper aerodigestive tract cancers

<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Cancer site</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>New York, 1992–1994, Zhang et al. (12)</td>
<td>Oral cavity, saliva gland, nasopharynx, oropharynx, hypopharynx, larynx, esophagus</td>
<td>173 SCC untreated cases from hospital, histologically confirmed</td>
<td>176 blood donors without history of cancer, frequency matched on age and sex</td>
<td>Questionnaire filled by subject</td>
<td>Ever use</td>
<td>2.6 (1–6.6)</td>
<td>• Adjusted for age, sex, race, education, alcohol use, pack-years of cigarette smoking, passive smoking</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frequency</td>
<td></td>
<td>• Association stronger for subjects ≤55 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 times/day</td>
<td>1.00</td>
<td>• Dose-response trend observed for both frequency (times per day) and duration (years) of marijuana use</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 times/day</td>
<td>4.0 (0.9–17.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;1 times/day</td>
<td>5.4 (0.9–33)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P for trend</td>
<td>0.024</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 years</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1–5 years</td>
<td>3.9 (0.9–15.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;5 years</td>
<td>4.9 (1.0–22.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P for trend</td>
<td>0.0164</td>
<td></td>
</tr>
<tr>
<td>Washington state, 1985–1995, Rosenblatt et al. (13)</td>
<td>Oral (tongue, gum, floor of mouth, tonsil, oropharynx, other intraoral sites)</td>
<td>407 carcinoma in situ and SCC cases, 18 to 65 years old, identified from the cancer registry, Response rate: 54.5% for 1985–1989, 63.3% for 1990–1995</td>
<td>615 subjects from random digit dialing, frequency matched on age and sex, Response rate: 61% for 1985–1989, 67% for 1990–1995</td>
<td>Face-to-face interviews with a structured questionnaire</td>
<td>Ever use</td>
<td>0.9 (0.6–1.3)</td>
<td>• Adjusted for birth year, sex, education, alcohol consumption, pack-years of cigarette smoking, study</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frequency</td>
<td></td>
<td>• Data are from 2 studies, one conducted in 1985–1989, the other in 1990–1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Never</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;1 year</td>
<td>1.0 (0.6–1.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;1 times/week</td>
<td>0.8 (0.5–1.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1–7 times/week</td>
<td>0.8 (0.4–1.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;7 times/week</td>
<td>0.5 (0.2–1.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Never</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;1 year</td>
<td>0.8 (0.4–1.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 year</td>
<td>0.2 (0.1–0.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1–5 years</td>
<td>1.3 (0.6–2.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;5–15 years</td>
<td>0.7 (0.4–1.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;15 years</td>
<td>1.2 (0.6–2.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK, 1990–1997, Llewellyn et al. (14)</td>
<td>Oral, oropharynx</td>
<td>146 SCCs of the oral cavity and oropharynx, ≤45 years old, identified from the cancer registry, Response rate: 59%</td>
<td>207 patients without cancer, matched individually to case by age, sex, residence. Response rate: not available.</td>
<td>Questionnaire filled by subject</td>
<td>Ever use</td>
<td>1.0 (0.5–2.2)</td>
<td>• Adjusted for age, sex, residence, and cigarette smoking</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Overall</td>
<td>0.9 (0.4–2.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Men</td>
<td>1.7 (0.4–7.0)</td>
<td></td>
</tr>
<tr>
<td>UK, 1999–2001, Llewellyn et al. (15)</td>
<td>Oral, oropharynx</td>
<td>53 SCCs of the oral cavity and oropharynx, ≤45 years old, identified from the cancer registry, Response rate: 80%</td>
<td>91 patients without cancer, matched individually to case by age, sex, residence. Response rate: not available.</td>
<td>Questionnaire filled by subject</td>
<td>Ever use</td>
<td>0.5 (0.1–1.8)</td>
<td>• Adjusted for age, sex, residence, alcohol, and cigarette smoking</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Overall</td>
<td>0.3 (0.1–3.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Men</td>
<td>0.7 (0.1–84.9)</td>
<td></td>
</tr>
<tr>
<td>Los Angeles, 1999–2004, Hashibe et al. (16)</td>
<td>Head and neck cancer (oral cavity, pharynx, and larynx) and esophageal cancer (19)</td>
<td>103 oral cavity, 70 pharyngeal, 90 laryngeal cancer cases from the cancer registry, Response rates: Oral cancer: 54%, Pharyngeal cancer: 45%, Laryngeal cancer: 42%, Esophageal cancer: 55%</td>
<td>1,046 cancer-free controls matched to cases on age, gender, and neighborhood, LA residents age 18 to 65. Response rate: 72%</td>
<td>Questionnaires by interviewers</td>
<td>Oral cancer</td>
<td>Never</td>
<td>Adjusted on age, gender, race, ethnicity, educational level, alcohol consumption</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Never smokers</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;0 to &lt;1 joint-years</td>
<td>0.93 (0.53–1.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11 to &lt;10 joint-years</td>
<td>1.5 (0.68–3.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥10 joint-years</td>
<td>1.8 (0.69–4.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pharyngeal cancer</td>
<td>Never</td>
<td>Adjusted on age, gender, race, ethnicity, educational level, alcohol consumption</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Never</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ever</td>
<td>0.92 (0.41–2.10)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Laryngeal cancer</td>
<td>Never</td>
<td>• Estimates shown are for never smokers</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Never</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ever</td>
<td>1.2 (0.26–5.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Esophageal cancer</td>
<td>Never</td>
<td>• Included in the Berthiller et al. pooled analysis (19) and Marks et al. pooled analysis (21)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Never</td>
<td>0.79 (0.30–2.1)</td>
<td></td>
</tr>
</tbody>
</table>

(Continued on the following page)
<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Cancer site</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Zealand, 2001–2005, Aldington et al. (17)</td>
<td>Oral cavity, oropharynx, nasopharynx, hypopharynx, pharynx, nasal cavities</td>
<td>75 cases, &lt;55 years old, from the New Zealand Cancer Registry and hospital databases</td>
<td>394 controls from electoral roll, frequency matched by age, and district health boards</td>
<td>Questionnaires by interviewers</td>
<td>Ever cannabis use</td>
<td>1.0 (0.5–2.3)</td>
<td>• Adjusted on age, sex, ethnicity, alcohol consumption, income, pack-years of cigarette smoking</td>
</tr>
<tr>
<td>Baltimore, MD, 2000–2006, Gillison et al. (18)</td>
<td>Head and neck squamous cell carcinomas (oral cavity, paranasal sinus, pharynx, larynx, unknown primary head and neck)</td>
<td>240 cases from a hospital</td>
<td>Two control subjects (n = 322) matched by age and sex to each HPV-16-positive and HPV-16-negative case subject from outpatient</td>
<td>Auto computer-assisted self-interview</td>
<td>Joint-years</td>
<td>0–9 joint-years: 1.0; 1–4 joint-years: 2.0 (0.76–5.2); 5–14 joint-years: 6.0 (1.2–29); ≥15 joint-years: 6.4 (1.6–26); P for trend: 0.003</td>
<td>• Adjusted on race, tobacco use, alcohol use, tooth loss, frequency of tooth brushing, and number of oral sex partners</td>
</tr>
<tr>
<td>South America and United States, 1985–2006, Berthiller et al. (19)</td>
<td>Head and neck cancer (oral cavity, pharynx, and larynx)</td>
<td>4,029 cases of head and neck cancers from five case-control studies within the INHANCE Consortium</td>
<td>5,015 controls of head and neck cancers from five case-control studies within INHANCE Consortium</td>
<td>Pooled self-reported questionnaire data</td>
<td>Oral cavity</td>
<td>Never: 1.0; &gt;0–2 joint-years: 0.73 (0.50–1.08); &gt;2–5 joint-years: 0.68 (0.32–1.46); &gt;5 joint-years: 0.73 (0.46–1.16); P for trend: 0.07</td>
<td>• Dose-response relations observed for both frequency (joints/month; P for trend = 0.007) and duration (years; P for trend = 0.01) among HPV-16-positive patients</td>
</tr>
<tr>
<td>Boston, MA, 1999–2003, Liang et al. (20)</td>
<td>Head and neck squamous cell carcinoma</td>
<td>434 cases identified from clinics and departments at nine medical facilities in Greater Boston, MA</td>
<td>547 controls matched to cases on age, gender, and town of residence, randomly selected from Massachusetts town books.</td>
<td>Self-administered questionnaire,</td>
<td>Lifetime marijuana (times/week + years)</td>
<td>Never: 1.0; &gt;0 to &lt;5: 0.63 (0.34–1.17); 5 to &lt;15: 0.36 (0.18–0.69); 15 to &lt;30: 0.53 (0.30–0.94); ≥30: 0.78 (0.41–1.47); P for trend: 0.03</td>
<td>• Adjusted for age, gender, race, education, HPV-16 serology, family history of cancer, smoking pack-years, and average alcohol drinks per week</td>
</tr>
</tbody>
</table>

(Continued on the following page)
their results separately. Investigation of the frequency of marijuana smoking (times per day) or duration (years) did not show any dose-response relations. The pooled analysis included 4,029 cases and 5,015 controls from North America and South America. Associations were not detected in an analysis restricted to never-tobacco users. The limitations of this study included potential recall bias because all the studies were case-control in design, fairly low prevalence of marijuana use in the study population, and possible differential misclassification of the exposure across countries or region due to different reporting of marijuana

Table 1. Epidemiologic studies on marijuana use and upper aerodigestive tract cancers (Cont’d)

<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Cancer site</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle, Latin America, Boston, Los Angeles, North Carolina, 1983–2013, Marks et al. (21)</td>
<td>Oropharyngeal and oral tongue cancer</td>
<td>1,921 oropharyngeal cases and 3,566 oral tongue cases from 9 case-control studies within INHANCE Consortium</td>
<td>7,639 controls from 9 case-control studies within INHANCE Consortium</td>
<td>Pooled self-reported questionnaire data</td>
<td>Joint-years</td>
<td>Oropharyngeal</td>
<td>Never</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Response rate: N/A</td>
<td>Response rate: N/A</td>
<td></td>
<td></td>
<td>Never</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Oral tongue</td>
<td>Never</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North Africa, 2002–2005, Feng et al. (22)</td>
<td>Nasopharyngeal carcinoma (NPC)</td>
<td>636 cases identified from five hospitals by clinicians in the oncology and radiotherapy departments</td>
<td>615 controls from Algeria, Morocco, and Tunisia. Matched by center, age, sex, and childhood household type (urban/rural)</td>
<td>Interviews</td>
<td>Lifetime frequency in men</td>
<td>Never</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;2,000 times</td>
<td>0.97 (0.37–2.52)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ 2,000 times</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Smoking cannabis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Smoking cannabis with tobacco</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: SCC, squamous cell carcinoma.
consumption. The strengths of this study included a large sample size, fairly high response rates, and adjustment on the same set of factors which would not be possible in a meta-analysis. The key strength is the reporting of estimates among never-tobacco users and never-alcohol users, which is difficult in individual studies due to limited sample sizes because the majority of patients with head and neck cancer are tobacco smokers and drinkers.

Liang and colleagues (20) observed a decreased risk of head and neck squamous cell cancer with marijuana use in a population-based case–control study of 434 cases and 547 controls matched to cases on age, gender, and town of residence in Boston from 1999 to 2003. ORs were adjusted for age, gender, race, education, family history of cancer, HPV-16 serology, smoking (pack-years), and average drinks of alcohol per week. Dose–response relations were observed for frequency, duration, cumulative exposure, years since last marijuana use and at age at start of marijuana use, and the risk of head and neck cancer. The limitations of this study include potential recall bias, possible residual confounding when adjusting on tobacco, and no differentiation between the subsites for head and neck cancers. Strengths of this study include adjustment and stratification on HPV-16 antibody status, tobacco and alcohol, and identification of dose–response trends.

In another INHANCE pooled data analysis, focusing on 1,921 oropharyngeal cases and 356 oral tongue cases and 7,639 controls, Marks and colleagues observed a possible increased risk in oropharyngeal cancer and a possible decreased risk in oral tongue cancer due to marijuana use with dose–response trends for both frequency and duration. The analysis included nine case–control studies from Baltimore; Seattle (407 cases and 615 controls; ref. 13), Latin America, Boston (434 cases and 547 controls; ref. 20), Los Angeles (493 cases and 1,040 controls; ref. 16), and North Carolina, which recruited subjects from 1985 to 2013 (21). The previous INHANCE report (19) had included 5 of these case–control studies; thus, 765 of the 1,921 oropharyngeal cancer cases and 211 of the 356 oral tongue cases had been included in the previous analysis. The OR estimates were adjusted for age, sex, race, education level, ever use of tobacco, ever use of cigarette/pipes, pack-years of tobacco smoking, and alcohol-year. When restricted to never-tobacco users and never-alcohol drinkers, the estimates for individual exposure categories were not significant; however, the trend for cumulative exposure was significant, and the risk estimate for > 10 joint-years was 3.94 (0.59–26.3). The OR for marijuana use adjusting on HPV status in the select studies with HPV data available suggested no association overall, although a decreased risk was observed for individuals who were HPV-16 negative. Limitations of this study were potential recall bias and different measurements of marijuana across the studies. Strengths of this study were large sample size due to the data pooling efforts, and stratified analysis by tobacco and alcohol, and adjustment and stratification on HPV where possible.

In the case–control study of nasopharyngeal cancer, Feng and colleagues (22) reported an increased risk between cannabis consumption of 2,000 times or more in a lifetime, and nasopharyngeal cancer risk in men after adjusting for age, socioeconomic status (SES), dietary factors, and cigarette smoking frequency. However, smoking cannabis alone did not appear to confer an increased risk of nasopharyngeal cancer (OR, 0.97; 95% CI, 0.37–5.52). This study included 636 cases and 615 controls in North Africa recruited between 2002 and 2005. Limitations of this study include potential recall bias, potential bias due to the inclusion of prevalent cases, using hospital controls, possible underestimation of cannabis consumption, the nearly universal reporting of tobacco cigarette smoking among cannabis users, and inability to disentangle effects of cannabis when mixed with tobacco and smoked in the form of a kif. Strengths of this study included the large sample size, adjustment for cigarette smoking, and the dose response observed for frequency and lifetime cannabis use.

Lung cancer

The six lung cancer studies were conducted in Los Angeles (16), Northern Africa (23, 24), New Zealand (25), Sweden (26), and in multiple locations for a pooled analysis (ref. 27; Table 2). Hsairi and colleagues (23) reported that cannabis use increased the risk of lung cancer by 8.2-fold (95% CI, 1.3–15.5) in a case–control study of 110 cases and 100 controls in Tunisia. Dose–response relations were not assessed in this study to our knowledge. Adjustments were made for age, sex, cigarettes smoked per day, water pipe use, and snuff use. Tobacco is mixed with marijuana in this region; thus, disentangling the effects of marijuana is difficult.

In the Los Angeles population-based case–control study of 611 lung cancer cases, dose–response relations were not observed between marijuana use and lung cancer after adjusting for age, gender, race/ethnicity, educational level, alcohol consumption, and cigarette smoking (16). In the analysis restricted to never-cigarette smokers, the ORs did not suggest an association between marijuana use and lung cancer. Strengths and limitations of this study were discussed above.

Berthiller and colleagues (24) pooled data from three separate hospital-based case–control studies, including 40 cases and 755 controls from Tunisia (45), Morocco (46), and Algeria, and reported an increased risk of lung cancer for ever marijuana use. Dose–response relations were not observed for frequency or duration alone, but a dose response was observed for cumulative joint-year exposure to cannabis. Limitations of the study include different questions used to assess marijuana use across the three studies, difficulty in separating out tobacco because all cannabis users were tobacco smokers, and in this region tobacco is mixed in with the cannabis. Strengths of the study include the increased sample size due to the data pooling approach, careful adjustment for tobacco use, and dose–response relations observed for cumulative exposure. The Voirin and colleagues study in Tunisia (45) and Sasco and colleagues study in Morocco (46) will not be reviewed separately because the entire data were included in the pooled analysis, and the analytic approach and results were very similar to the pooled study it contributed to.

In the New Zealand case–control study of lung cancer, Aldington and colleagues (25) reported an increased risk of lung cancer in young adults (<55 years) due to heavy cannabis use (>10.5 joint-years) after adjusting for age, sex, ethnicity, a family history of lung cancer, pack-years of cigarette smoking. Dose–response relations were observed for joint-years of cannabis use. The study of lung cancer included 79 cases and 324 controls matched in 5-year age groups in New Zealand between 2001 and 2005. The limitations of the study were a fairly small sample size (only 4 controls and 14 cases in the subgroup with >10.5 joint-years of cannabis use), resulting in imprecise estimates of risk in this subgroup, and potential recall bias. The strengths of the study included the population-based design, and dose response identified for cumulative joint-years of cannabis exposure.

The cohort study on lung cancer included 48,321 young men ages 18 to 20 years old during military conscription in Sweden from 1969 to 2009 (26). Ever cannabis smoking was not clearly
Table 2. Epidemiologic studies on marijuana use and lung cancer

<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tunisia, 1988–1989, Hsairi et al. (23)</td>
<td>110 cases diagnosed in a hospital, 70.0% have histological confirmation, 97.3% male.</td>
<td>110 residents in Tunisia, individually matched on age, sex, and average number of cigarettes/day</td>
<td>Face-to-face interviews with questionnaire</td>
<td>Cannabis use</td>
<td>8.2 (1.3–15.5)</td>
<td>• Adjusted for age, sex, number of cigarettes/day, water pipe use, and snuff use</td>
</tr>
<tr>
<td>Los Angeles, CA, 1999–2004, Hashibe et al. (16)</td>
<td>611 lung cancer cases from the cancer registry</td>
<td>1,040 cancer-free controls matched to cases on age, gender, and neighborhood. LA residents age 18 to 65.</td>
<td>Subjects were interviewed face-to-face with a standardized questionnaire</td>
<td>Never ≥ 0 to 1 joint-years ≥1 joint years Never smokers</td>
<td>0.44 (0.21–0.92) 1.1 (0.48–2.6)</td>
<td>• Adjusted for age, gender, race/ethnicity, educational level, and alcohol consumption</td>
</tr>
<tr>
<td>Tunisia, Morocco, Algeria, 1996–2004, Berthiller et al. (24)</td>
<td>430 cases from 3 study hospitals</td>
<td>755 hospital-based controls</td>
<td>Pooled self-reported questionnaire data</td>
<td>Ever cannabis use</td>
<td>2.4 (1.5–3.7)</td>
<td>• Adjusted on age, occupational exposure, country, years of tobacco smoking</td>
</tr>
<tr>
<td>New Zealand, 2001–2005, Aldington et al. (25)</td>
<td>79 cases identified from the New Zealand Cancer Registry and hospital database. Age &lt; 55 years.</td>
<td>324 controls matched in 5-year age groups and district health boards</td>
<td>Interviewer-administered questionnaires</td>
<td>Cannabis use</td>
<td>1.0 0.3 (0.1–1.7) 0.5 (0.1–2.0) 5.7 (1.5–21.6)</td>
<td>• Adjusted for age, sex, ethnicity, pack-years of cigarette smoking, and family history of lung cancer</td>
</tr>
<tr>
<td>Sweden, 1969–2009, Callaghan et al. (26)</td>
<td>179 lung cancer cases</td>
<td>Self-reported questionnaires. The 1969 to 1970 conscription collected information about alcohol and drug use</td>
<td>Ever Cannabis smoking</td>
<td>Lifetime frequency</td>
<td>1.25 (0.84–1.87)</td>
<td>• Adjusted for cigarette smoking (frequency), alcohol consumption, respiratory conditions,</td>
</tr>
</tbody>
</table>

(Continued on the following page)
associated with lung cancer risk. The authors noted that a clear
dose–response relationship was not present after adjusting for
tobacco smoking, level of alcohol consumption, respiratory con-
ditions, and conscripts’ SES in 1970. An increased lung cancer risk
was observed for men who smoked cannabis more than 50 times
by the time of conscription (26). Limitations of this study include
self-report of cannabis smoking at conscription which was not
anonymized and may lead to underreporting. Other limitations
include lack of detailed information of use on patterns of cannabis
or tobacco before conscription and after conscription, misclassi-
fication biases of unmeasured postconscription changes in mar-
ijuana or tobacco use, and potential residual confounding due to
tobacco smoking because 91% of the cannabis smokers were also
tobacco smokers. They were not able to adjust for true lifetime use
of tobacco including use during the 40-year follow-up period, but
adjusted only for tobacco use up to the time of conscription at ages
18 to 20 years in this study. The authors noted that it is also possible
that tobacco was mixed with cannabis, although the habits and culture at the time (1969–70) are unclear. The strengths of this study were the cohort design, large sample size
of the cohort, and having a long follow-up period of 40 years.

In a pooled data analysis of lung cancer including of 6 case–
control studies, Zhang and colleagues (27) reported that
there were no dose–response relationships observed between
cannabis smoking and lung cancer after adjusting for age, sex,
highest education, and study, reporting on never-tobacco
smokers. This pooled analysis included 2,159 cases and 2,985
controls from studies conducted in Los Angeles (16), New York,
Florida, Canada, the United Kingdom, and New Zealand (25).
The Los Angeles (611 cases/1,040 controls) and New Zealand
(79 cases and 324 controls) studies reviewed here were included
in this pooled analysis. The four other studies included in the
pooled analysis did not publish their results on marijuana
use, to our knowledge. The limitations of this study were
potential recall bias and the heterogeneity of marijuana expo-
sure assessment across the studies. The strengths of this study
consisted of the large sample size due to data pooling efforts, and
the investigation of lung cancer risk among never-tobacco
smokers.

**Table 2. Epidemiologic studies on marijuana use and lung cancer (Cont’d)**

<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
</table>
| US, Canada, UK, and New Zealand, 2010, Zheng et al. (27) | 2,159 cases from 6 case-control studies in the lung cancer (ILCCO) consortium | Response rate: N/A | Pooled self-reported questionnaire data | Never-tobacco smokers | 1.00 | • Adjusted for age, sex, highest education, and study
• Estimates presented are for never-tobacco smokers
• Included the published studies from Los Angeles (16) and New Zealand (25) |
| | 2,985 controls from 6 case-control studies in the lung cancer (ILCCO) Consortium | Response rate: N/A | | Nonhabitual cannabis smoker | 1.03 (0.51–2.08) | |
| | | | | Habitual Joint-years | $<1$ joint-years | 1.00 |
| | | | | | 1 to <30 joint-years | 1.26 (0.57–2.75) |
| | | | | | $>30$ joint-years | 0.54 (0.32–0.85) |
| | | | | | Continuous joint-years | 1.00 (0.93–1.07) |

**Testicular cancer**

In a population-based case–control study of testicular cancer,
Daling and colleagues (28) observed an association between ever
marijuana use and testicular cancer after adjusting for age, refer-
ence year, alcohol use, current smoking, and history of cryptorchidism (Table 3). Increased testicular cancer risks were observed
in categories of frequency and duration of marijuana use for
current marijuana users, although dose–response relations were
not obvious. The study included 369 cases ages 18 to 44 years old
and 979 age-matched controls who resided in the same three
counties in the United States from 1999 to 2006. The limitations
of this study consisted of potential recall bias due to self-report of
use of marijuana and a small number of categories of marijuana
use. The strengths of this study were that this is the largest
testicular cancer study published to date and had a population-
based design.

Trabert and colleagues (29) reported that there was an
increased risk of testicular cancer with daily marijuana use after
adjusting for age, race, alcohol use, cigarette smoking, and history of cryptorchidism. The study included 187 cases and 148 controls
from Texas, Louisiana, Arkansas, and Oklahoma from 1990 to
1996. The limitations of this study were potential recall bias,
inability to evaluate current use with data because only less <10%
of their study population reported current marijuana use, and
difficulty interpreting the temporal relationship between mari-
jana and testicular germ cell tumors.

Lacson and colleagues (30) observed an increased risk of
testicular cancer with marijuana use after adjusting for cocaine
use, amyl nitrite use, cryptorchidism, religiosity, and education.
This study included 163 cases and 292 controls matched on age,
race/ethnicity, and neighborhood in Los Angeles county
from 1986 to 1991. Higher testicular cancer risk was observed
in the lower frequency and duration categories, although the
differences were not statistically significant. Limitations of
this study were potential recall bias, and a small number of
categories for the frequency of use of marijuana. Strengths of
this study were that the categories used in the other two
testicular cancer studies were similar and thus more easily comparable.
We conducted a meta-analysis of these three studies (Table 4) and observed no association with ever use of marijuana and testicular cancer risk. However, for the upper category of frequency of marijuana use, a 1.56-fold (95% CI, 1.09–2.23) increase in testicular cancer risk was observed. Similarly, for 10 or more years of marijuana smoking, a 1.5-fold (95% CI, 1.08–2.09) increase in testicular cancer risk was observed.

Childhood cancers

Five of the six studies on childhood cancers and marijuana use were based on the Children’s Cancer Study group. Parental marijuana use during the gestational period was associated with childhood leukemia (31, 32), astrocytoma (33), and rhabdomyosarcoma (ref. 34; Table 5). These studies shared limitations such as small numbers of exposed cases, possible exposure misclassification due to the potential recall bias, and no dose–response assessments. Strengths consisted of large sample size and information on use of specific recreational drugs within specific time periods relative to pregnancy and birth.

In the case–control study of childhood acute myelogenous leukemia, Trivers and colleagues (35) observed no association of childhood acute myeloid leukemia with parental marijuana use. This study included 638 cases who were age <18 years old and 610 controls matched on age and resident location in Washington State from 1999 to 2006. Although paternal ever marijuana use appeared to be associated with the risk of childhood acute myelogenous leukemia, assessment of specific time periods relative to the pregnancy and birth did not support an association. Furthermore, frequency of maternal marijuana use was not associated with leukemia risk.

In the case–control study of childhood neuroblastoma, Bluem and colleagues (36) did not observe an association of an increased risk of childhood neuroblastoma after adjusting for household income in the year of birth and age at diagnosis in three categories and other drugs used. An increased risk of neuroblastoma was observed for maternal marijuana use in the first trimester, with 4-fold increases in risk for the categories of frequency of use. The study of childhood neuroblastoma included 538 cases and 504 controls matched on age in North America from 1992 to 1994.
Table 5. Epidemiologic studies on marijuana use and childhood cancers

<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Cancer site</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
</table>
| Multicenter, US, and Canada, 1980–1984, Robison et al. (31) | Childhood acute nonlymphoblastic leukemia | 204 cases, identified in registry of Children’s Cancer Study Group, diagnosed at <18 years of age, Response rate: 77.9% | 204 subjects from random digit dialing, individually matched on date of birth, race, telephone area code, and exchange | Telephone interviews of mothers and fathers of subjects, with structured questionnaire | Maternal use of mind-altering drugs during or in the year before the pregnancy | 1.47, P = 0.32 | • Adjusted for date of birth, race, residence, telephone area code  
• 9 of 11 cases had maternal marijuana only  
• The authors reported that adjustment for mother’s age, education, tobacco use, alcohol did not result in reduction in risk or loss of statistical significance |
| Multicenter, US, Canada, and Australia, 1983–1993, Wen et al. (32) | Childhood leukemia | 1,805 acute lymphoblastic leukemia cases, 528 acute myelogenous leukemia, age <20 months, selected from registration files of the Children’s Cancer Study Group | 2,723 subjects from random digit dialing, individually matched on year of birth, telephone area code, and exchange number | Telephone interviews of mothers and fathers of subjects, with structured questionnaire | Ever marijuana use by father | 1.5 (P < 0.05) | • Adjusted for year of birth, telephone area code, exchange number  
• Dose–response assessment not available |
| Pennsylvania, New Jersey, Delaware, US, 1980–1986, Kujitien et al. (33) | Childhood astrocytoma | 163 cases, identified through 8 hospital tumor registries, diagnosed at <15 years, Response rate: 80% | 163 subjects from random digit dialing, individually matched on year of birth, telephone area code, and exchange number | Telephone interviews of mothers and fathers of subjects, with structured questionnaire | Gestational marijuana exposure | 2.8 (0.9–9.9) | • Adjusted for age, race, residence, dose–response relations not assessed  
• Data on paternal use not presented |
| Multicenter, US, 1982–1988, Grufferman et al. (34) | Childhood rhabdomyosarcoma | 322 cases, identified in the registry of the Children’s Cancer Study Group, diagnosed at 0–20 years of age | 322 subjects from random digit dialing, individually matched on age, sex, race | Telephone interviews of mothers and fathers of subjects, with structured questionnaire | Maternal use of marijuana | 3.0 (1.4–6.5) | • Adjusted for age, sex, race, birthmarks on child, bleeding/cramping during pregnancy, prematurity of child  
• Factors associated with rhabdomyosarcoma in data were adjusted for |
| Multicenter, US, and Canada, 1989–1993, Trivers et al. (35) | Childhood acute myeloid leukemia | 618 cases age <18 identified from the Children’s Cancer Group, Response rate: 83% | 610 matched controls, Matched to the cases on age and residential location. Using a random digit dialing procedure. | Telephone interviews of mothers and fathers of subjects, with structured questionnaire | Maternal and paternal marijuana use in specific time periods did not support an association  
Frequency of marijuana use was not associated (data not presented in publication) | 1.00 | • Adjusted for age at the index child’s birth, parental education, household income, alcohol consumption and cigarette smoking before, during, and after pregnancy, maternal history of fetal loss before the index pregnancy, and birth order  
• Maternal and paternal marijuana use in specific time periods did not support an association  
• Frequency of marijuana use was not associated (data not presented in publication) |
Other cancers

In a large cohort study of 64,855 individuals in California, marijuana use was not associated with cancer risk nor with tobacco-related cancers, after adjustment for age, race, education, alcohol use, and cigarette smoking (ref. 37; Table 6). In the subgroup analysis of never-tobacco smokers, marijuana use was associated with an increased risk of prostate cancer and cervical cancer. Dose–response relations with frequency and duration of marijuana use were not observed with cancer risk nor with the risk of specific cancer sites. Daling and colleagues (38) reported on 148 anal cancer cases and reported no association with ever marijuana use when compared with 166 colon cancer cases. Penile cancer risk was also not associated with marijuana use according to a study of 110 cases and 355 controls (39).

The two case–control studies on non-Hodgkin lymphoma reported on null to possibly protective associations (40, 41). In the study including 1,281 cases and 2,093 controls from Northern California, a 50% reduction in risk for men was observed for a 1,000 or more times marijuana use and a 40% reduction in risk for women was observed for 40 to 999 times marijuana use (41). However, protective associations were also observed for sexual behaviors and cocaine use; thus, it is unclear whether the associations between marijuana use and lymphoma risk were due to residual confounding.

In another California cohort of 105,005 individuals, marijuana use at a frequency of one or more times per month appeared to increase the risk of malignant primary glioma (42) after adjustment for smoking status, sex, race, alcohol, education, and coffee intake. Although the cohort design was a strength, the small number of cases (n = 69) was a limitation in the study.

In the case–control study of transitional cell carcinoma of the bladder, Chacko and colleagues (43) observed a significant association of transitional cell carcinoma and marijuana after adjusting for agent orange exposure, radiation exposure, and dye exposure, with dose–response relations. The study of transitional cell carcinoma included 52 cases age <60 years old and 168 controls in the United States. The limitations of this study were small sample size, potential recall bias due to self-report, and lack of adjustment on tobacco smoking which is an established risk factor for bladder cancer.

The Kaposi sarcoma cohort study was a U.S. multicenter study of natural-treated histories of HIV-1 infection in men who have sex with men (44). The study was started in 1984 and had three recruitment periods with emphasis on enrolling more ethnically diverse men in the later periods: 1984 to 1985, 1987 to 1991, and 2001 to 2003. Of the 1,335 white men included in the study, 401 Kaposi sarcoma cases were identified and included in the analysis. Recent use of any of four drugs (marijuana, cocaine, poppers, and amphetamine) was not associated with Kaposi sarcoma risk, after adjusting for age, college education, study center, alcohol use, tobacco smoking, number of male sexual partners since the last study visit, lifetime number of sexual partners, receptive anal intercourse and condom use, antiretroviral therapy, CD4 cell count, and sexually transmitted infection score. Limitations of this study were the self-report of drugs, prespecified categories for frequencies of marijuana use, and lack of consistent testing for HHV-8 from all participants which lead to many individuals being excluded from the analysis. Strengths of this study were large sample size, having a long follow-up period, the ability to examine the effect of substance use from different exposure periods, and adjusting for multiple potential confounders.
<table>
<thead>
<tr>
<th>Study location, Cancer site</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>California, US, 1979–1999, All sites, and selected sites</td>
<td>1,421 cancers</td>
<td>Cohort of 64,855 Kaiser Permanente subscribers who received health checkups, ages 15 to 49 years, follow-up through cancer registry and death records</td>
<td>Self-administered questionnaires</td>
<td>Ever and current use</td>
<td>1.00 (0.50–1.48)</td>
<td>Men, nontobacco smokers 0.8 (0.5–1.2), 0.8 (0.2–2.9), 0.7 (0.2–2.1), 0.5 (0.2–1.3), 3.1 (1.0–9.5), 1.1 (0.8–1.3), 0.3 (0.0–2.5), 1.0 (0.4–2.3), 0.8 (0.5–1.3), 1.4 (1.0–2.1)</td>
</tr>
<tr>
<td>Washington, US, and Canada, 1978–1985, Anal</td>
<td>148 cases identified through the cancer registry, &lt;70 years of age, of all histologic types, including in situ and invasive lesions. Interviews conducted for 71.2% of eligible cases identified.</td>
<td>66 colon cancer cases identified through the cancer registry, individually matched on age, sex, year of diagnosis, and geographic area. Interviews available for 67.3% of eligible subjects.</td>
<td>Face-to-face interviews with questionnaire</td>
<td>Ever use</td>
<td>0.8 (0.2–4.0)</td>
<td>Adjusted for age, residence, cigarette smoking (never, formerly, currently), geographic area. Dose-response relations not assessed</td>
</tr>
<tr>
<td>Washington, US, and Canada, 1979–1990, Penile</td>
<td>110 cases, identified through the cancer registry, &lt;74 years old, including squamous carcinoma and in situ. Response rate: 50.2%</td>
<td>355 subjects from random digit dialing, frequency matched on age, reference year, Response rate: 70.3%</td>
<td>Face-to-face interviews with questionnaire</td>
<td>Ever use</td>
<td>1.5 (0.7–2.3)</td>
<td>Adjusted for age, alcohol consumption, cigarette smoking (never, former, current), number of sexual partners</td>
</tr>
<tr>
<td>California, US, 1989–1992, Nelson et al. (40)</td>
<td>Non-Hodgkin lymphoma</td>
<td>578 subjects individually matched on age, sex, race/ethnicity, neighborhood of residence, and interview language</td>
<td>Face-to-face interviews with questionnaire</td>
<td>Lifetime use (men)</td>
<td>No use 1.00, Any use 0.86 (0.50–1.48), 1–5 times 0.68 (0.34–1.38), 6–490 times 0.93 (0.46–1.88), ≥ 901 times 1.09 (0.48–2.48)</td>
<td>Adjusted for age, sex, race/ethnicity, neighborhood of residence, and interview language</td>
</tr>
</tbody>
</table>

(Continued on the following page)
Table 6. Epidemiologic studies on marijuana use and other cancers (Cont’d)

<table>
<thead>
<tr>
<th>Study location, period, author, reference</th>
<th>Cancer site</th>
<th>Characteristics of cases</th>
<th>Characteristic of controls or cohort</th>
<th>Exposure assessment</th>
<th>Exposure categories</th>
<th>RR or OR (95% CI)</th>
<th>Adjustment for potential confounders and other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>California, US, 1988–1995, Holly et al. (41)</td>
<td>Non-Hodgkin lymphoma</td>
<td>1,281 cases identified through the Northern California cancer registry, ages 21 to 74. Overall % interviewed of NHL cases ~56.7%.</td>
<td>2,095 subjects from random digit dialing, frequency matched on age, sex, residence. 78% of eligible controls completed interviews</td>
<td>Face-to-face interviews with structured questionnaire</td>
<td>Number of times used</td>
<td>Women</td>
<td>Adjusted for age</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.00</td>
<td>0.56 (0.40–0.77)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.58 (0.35–0.97)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.71 (0.34–1.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Adjusted for age</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Estimates adjusted for age, education, sexual partners, vaccinations, medications, and other factors were significant for men, and for men and women combined</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Adjusted for age, education, sexual partners, vaccinations, medications, and other factors were significant for men, and for men and women combined</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Adjusted for age, education, sexual partners, vaccinations, medications, and other factors were significant for men, and for men and women combined</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Adjusted for age, education, sexual partners, vaccinations, medications, and other factors were significant for men, and for men and women combined</em></td>
<td></td>
</tr>
<tr>
<td>California, US, 1977–1999, Bird et al. (42)</td>
<td>Malignant primary glioma</td>
<td>69 cases of glioma</td>
<td>Cohort of 105,005 Kaiser Permanente subscribers who received health checkup, ages ≥25 years, follow-up through cancer registry</td>
<td>Self-administered questionnaires</td>
<td>Ever use</td>
<td>1.9 (0.9–4.0)</td>
<td>Adjusted for smoking status (cigarettes, cigars, pipes), sex, race, alcohol, education, coffee intake</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.6 (0.1–4.4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.8 (13–62)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.3 (0.8–2.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.08</td>
<td></td>
</tr>
<tr>
<td>US, Chacko et al. (43)</td>
<td>Transitional cell carcinoma of bladder</td>
<td>52 cases age &lt;60 with transitional cell carcinoma of bladder from hospitals. Response rate = 88.5%</td>
<td>168 age-matched controls</td>
<td>Response rate = 69.2%</td>
<td>A self-administered questionnaire</td>
<td>Marijuana</td>
<td>Ever smoked</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Current smoke</td>
<td>1.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Joint-years&lt;40</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.25 (0.87–1.79)</td>
<td><em>Adjusted for age, education, study center, alcohol use, tobacco smoking, number of male sexual partners, lifetime number of sexual partners, receptive anal intercourse and condom use, antiretroviral therapy, CD4 cell count, and sexually transmitted infection</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Five year lag was applied for exposure</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Duration of use was not available</em></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: NHL, non-Hodgkin lymphoma.
Discussion

The largest number of studies for a cancer site under investigation for the impact of marijuana use appears to involve head and neck cancer. There were a total of 8 case-control studies and 2 pooled analysis studies on head and neck cancer and marijuana use. One study reported an increased risk (12), five studies reported no association (13–17), and one study reported a decreased risk of head and neck cancer (20). Of the five studies reporting no association, two of the studies were very small in sample size (<100 cases) and may have limited power to detect associations. Gillison and colleagues (18) reported no association between marijuana use and head and neck cancer for HPV-16-negative patients and an increased risk for HPV-16–positive patients. The pooled analyses have reported no overall association for head and neck cancer (19), but a possible increased risk with dose response for oropharyngeal cancer and a decreased risk for oral tongue cancers (21). In the head and neck cancer pooled analysis (19), two of the published studies (13, 16) out of the five studies pooled were included, whereas the oropharyngeal/oral tongue pooled analysis included 3 published studies (13, 16, 20) out of the 9 studies pooled. The evidence is inconsistent but may be consistent with no association or with opposite directions of association depending on subgroups of populations. The three studies that investigated HPV and marijuana on the risk of head and neck cancer suggest that HPV may be a modifying factor between marijuana use and head and neck cancer risk (18, 20, 21).

For lung cancer, there are three published case-control studies (16, 23, 25), one cohort study (26), and two pooled analysis studies (24, 27). The North African studies are consistent in reporting increased risks of lung cancer (23, 24) with dose–response relations. However, tobacco is mixed with cannabis in the region; thus, it is difficult to rule out residual confounding by tobacco smoking. The study in New Zealand (25) reported an increased risk with dose response for cumulative exposure, whereas the study in Los Angeles reported no association (16). Both of these studies were included in the lung cancer consortium pooled analysis, which was recently published (27), and reported no overall association and no dose–response relations. The cohort study on lung cancer reported an increased risk for marijuana use with a dose–response for the number of times used in a lifetime, but "lifetime" use was assessed only up until the ages of 18 to 20 years with no information on subsequent use over the <40-year follow-up period and no dose–response for frequency. The lung cancer studies appear to be consistent with no association with marijuana, although affirming no association is inherently difficult.

Highest exposure categories as presented in studies on marijuana use and lung cancer ranged from >50 lifetime frequency* (i.e., approximately 1 joint/week for one year, or 1/7 joint-year) in one study, > 1 or 2 joint-years in two studies, to > 10 joint-years in two other studies. Even the 10 joint-years of cumulative lifetime use of marijuana would translate into only 0.5 pack-years of cigarette smoking, assuming similar carcinogenic potency and similar amount of tobacco used in joints and cigarettes. In most studies on tobacco smoking and lung cancer, such a cumulative exposure would be classified as never smoker. Further, assuming a relative risk of 1.2 for lung cancer for a cumulative cigarette smoking of 2 to 4 pack-years, and making the same assumptions as above, a similar relative risk of lung cancer would require 40 to 80 joint-years of marijuana use, a lifetime use hardly seen in any of the studies reviewed here.

That marijuana smoking may be a risk factor for the development of cancer is suggested by several lines of evidence. First, the tar phase of marijuana smoke contains at least similar amounts of some procarcinogenic polycyclic aromatic hydrocarbons (PAH), including benz(a)pyrene and benzanthracene, to those of the tar obtained from the smoke of the same quantity of tobacco (47–49).

Second, although marijuana is generally smoked in lower amounts than tobacco, the prolonged breathing time during marijuana smoking and the reduced rod filtration due to more loosely packed marijuana lead to a 4-fold increase in the respiratory deposition of tar (which contains the carcinogenic PAHs) compared with the deposition of tar from the smoking of a comparable quantity of tobacco (50). This greater lung deposition from marijuana smoking, along with the higher concentration of some known carcinogens in marijuana smoke, is likely to magnify the level of exposure to carcinogens from each marijuana cigarette. Third, delta-9 tetrahydrocannabinol (THC), the major psychoactive ingredient in marijuana, can interact with the aryl hydrocarbon receptor, activating transcription of cytochrome P4501A1 (51), which is involved in the biotransformation of PAHs into active carcinogens. Fourth, hamster lung explants exposed to marijuana smoke for up to 2 years exhibited abnormalities in cell growth and accelerated malignant transformation (52). Fifth, non–small cell lung cancer cell lines implanted into immunocompetent mice exhibited accelerated growth when the animals were injected intraperitoneally with THC, a finding that was associated with THC-induced overproduction of immunosuppressive cytokines (IL10 and TGFβ) and underproduction of immunostimulatory cytokines (IL2 and INFγ), consistent with a THCB-related, cytokine-dependent inhibition of antitumor immunity (53). Sixth, endobronchial biopsies obtained from habitual smokers of marijuana without a history of tobacco smoking have demonstrated a number of histopathologic alterations, including squamous metaplasia, cellular atypia, and increased nuclear/cytoplasmic ratio, that are considered to be premalignant (54, 55). Seventh, immunohistochemical assessment of these biopsies has shown significantly increased expression of molecular markers of premalignant progression, including EGF and Ki-67 (a nuclear proliferation protein) compared with nonsmokers (56).

In view of the above findings, a null association between marijuana use and lung cancer is somewhat surprising because marijuana smoke contains known carcinogens in amounts comparable with those found in tobacco smoke (49). Although the generally smaller amounts of marijuana that are regularly smoked compared with tobacco might appear to explain the null association of marijuana with lung cancer, the absence of a dose–response relationship between marijuana use and lung cancer, in contrast to the strong dose–response relationship noted for tobacco (16), would argue against this explanation. A more likely explanation is a tumor-suppressant effect of THC and other cannabinoids evident in both cell culture systems and animal models of a variety of cancers, as reviewed by Bifulco and colleagues (57). These antitumoral effects (antimitogenic, proapoptotic, and antiangiogenetic) could possibly counteract the tumor-initiating or tumor-promoting effects of the carcinogens within the smoke of cannabis.

The three testicular cancer case–control studies were fairly consistent with one another in terms of an increased risk observed even for fairly moderate frequency and duration of use (28–30). It
Marijuana is most commonly smoked (with or without tobacco with food). The studies to date assumed marijuana was smoked, to our knowledge, and did not ask about how the marijuana was used. Marijuana is most commonly smoked (with or without tobacco depending on the geographic region), but can also be ingested with food.

Some future study recommendations are as follows.

Focus on never-tobacco smokers

If possible never-tobacco smokers are an ideal group to study association between marijuana smoking and smoking-related cancers because the effect of marijuana use on cancer can be more easily disentangled from the effect of tobacco smoke on cancer risk. In another words, the potential independent effect of marijuana can be better characterized. The possibility of residual confounding in any associations observed will be minimized if the study population is restricted to never smokers.

Adjust carefully for tobacco smoking

If tobacco smokers are in the study population, the adjustment for tobacco smoke should include multiple variables such as tobacco smoking status (never, past, current), frequency, duration, and years since quitting. Adjustment on only tobacco smoking status (never, past, current) for example may leave residual confounding. If the cancer under study is not associated with tobacco smoking, adjustment for tobacco smoking is not necessary because it does not meet the three properties of confounders. However, as a conservative approach, it would be useful to report on estimates adjusted for tobacco smoking separately, even if the cancer under study is not a tobacco-related cancer.

Report on groups of subsites of head and neck cancers

Because the results of previous studies suggest substantial heterogeneity in the risk estimates according to head and neck cancer subsites, risk estimates for marijuana use should be reported separately by subsite. Because head and neck cancer subsites have different etiology, e.g., oropharynx cancers are strongly related to HPV, and those HPV-positive cancers perhaps may not be strongly related to tobacco and alcohol, risk conferred by marijuana use may also differ.

Stratification by HPV status for cancers of the oropharynx

Previous studies also suggest that HPV status may be a potential modifier of the marijuana and oropharyngeal cancer association, and results should be stratified on HPV status when studying oropharyngeal cancer. Interactions should be assessed between HPV status and marijuana use with statistical tests.

Conduct a prospective cohort design

The majority of previous studies have been case–control, which have the inherent limitation of potential recall bias. To minimize recall bias and study multiple cancer sites, a prospective cohort study design is preferably for future studies focusing on the association between marijuana use and cancer risk. Conducting the study in regions/states where marijuana use is legalized with a sizable proportion of long-term and heavy users would likely reduce reporting bias and increase the power of the study. Further, the cohort design would allow investigation of the full range of cancers potentially associated with marijuana use.

Continue data pooling efforts

Though we conducted a meta-analysis for testicular cancer, the estimates were not adjusted for the same factors; thus, a pooled analysis for testicular cancer would be very informative. In addition, one of the studies had restricted the frequency and duration estimates to current users instead of both current and past users; thus, the estimates were not entirely comparable. The potential independent effect of marijuana can be better characterized. The possibility of residual confounding in any associations observed will be minimized if the study population is restricted to never smokers.

**Future study recommendations**

Collect specific information on the type of marijuana use

The studies to date assumed marijuana was smoked, to our knowledge, and did not ask about how the marijuana was used. Marijuana is most commonly smoked (with or without tobacco depending on the geographic region), but can also be ingested with food.
Additional analyses of studies on head and neck cancer and lung cancer

Although large-scale pooled analyses have been conducted for both head and neck cancer and lung cancer, additional efforts to elucidate some of the issues raised above (e.g., type of marijuana use), and if possible, additional analyses of HPV status for oropharyngeal cancer are warranted.

The development of marijuana-related biologic markers in future epidemiologic studies

It is of importance to develop and validate marijuana smoking–related exposure markers including DNA adducts; exposure-related early biologic responses such as specific somatic mutations of tumor suppressor gene; genetic polymorphisms of metabolic, inflammation, and DNA repair genes; and epigenetic markers including DNA methylation, microRNA, etc.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by a grant from the National Institute of Dental and Craniofacial Research at the NIH (R01 DE023414; to M. Hashibe). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 3, 2014; revised October 6, 2014; accepted October 6, 2014; published online January 13, 2015.

References

Marijuana and Cancer Review

References


An Epidemiologic Review of Marijuana and Cancer: An Update

Yu-Hui Jenny Huang, Zuo-Feng Zhang, Donald P. Tashkin, et al.


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/24/1/15

Cited articles
This article cites 47 articles, 9 of which you can access for free at:
http://cebp.aacrjournals.org/content/24/1/15.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/24/1/15.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cebp.aacrjournals.org/content/24/1/15.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.